International Stem Cell (ISCO) AI Stock Analysis

• Market Cap: $1.00M
• Dividend Yield: N/A
• Average Volume (3M): 1.48K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.52
• Revenue Growth: 16.64%
• EPS Growth: 27.03%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 8,004,389
• 10 Day Avg. Volume: 178
• 30 Day Avg. Volume: 1,479
• PEG Ratio: -0.07
• Price to Book (P/B): -0.22
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.68
• Enterprise Value/Market Cap: 3.49
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 0.66
• Enterprise Value/Ebitda: -6.97
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

International Stem Cell's stock is rated low due to significant financial challenges, including negative profitability and high leverage. While there is some positive momentum in technical analysis, the valuation remains unattractive due to the lack of profitability. Improvements in financial stability and strategic changes are necessary to enhance the overall stock rating.

International Stem Cell Business Overview & Revenue Model

Company Description

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. The company's human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

How the Company Makes Money

ISCO generates revenue through multiple streams, primarily from the sale of biomedical products, licensing agreements, and partnerships. The company develops and sells specialized cell culture media and reagents used in stem cell research and therapy development. Additionally, ISCO has a skincare product line under the brand 'Lifeline Skin Care,' which leverages its stem cell technology. Revenue is also derived from strategic partnerships and collaborations with other biotech firms and research institutions, which may include joint development agreements, licensing its proprietary technologies, and receiving milestone and royalty payments.

International Stem Cell Financial Statement Overview

Summary

International Stem Cell faces significant financial challenges, with consistent losses and high leverage. Revenue growth is a positive aspect, but profitability and cash flow issues persist. Financial restructuring or strategic changes may be needed to improve stability and reduce debt reliance.

Income Statement

The company has shown moderate revenue growth, with a 16.6% increase from 2023 to 2024. However, consistent negative net income and EBIT margins indicate ongoing operational challenges. Gross profit margin is healthy at 58.6% for 2024, but the net profit margin remains negative at -2.3%, showing profitability issues.

Balance Sheet

The balance sheet is weak due to high leverage, with a debt-to-equity ratio of 1.20 for 2024. Although stockholders' equity turned positive, it remains low. The equity ratio is concerning at 7.2%, indicating significant reliance on debt. Improving equity levels could enhance financial stability.

Cash Flow

Free cash flow turned negative in 2024, dropping significantly from the previous year. The operating cash flow to net income ratio is positive, but the overall cash flow position is weak, with a free cash flow to net income ratio of 0.73. Persistent cash flow challenges pose liquidity risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
9.09M	7.79M	8.18M	7.18M	7.13M
	Gross Profit
5.32M	4.61M	4.91M	4.24M	4.35M
	EBIT
-68.00K	-663.00K	-196.00K	-1.92M	-2.82M
	EBITDA
142.00K	202.00K	22.00K	-220.00K	-2.36M
	Net Income Common Stockholders
-209.00K	-131.00K	-466.00K	-1.04M	-2.84M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.23M	1.59M	742.00K	171.00K	689.00K
	Total Assets
5.17M	5.39M	5.13M	4.95M	5.29M
	Total Debt
3.84M	4.18M	4.28M	4.07M	4.32M
	Net Debt
2.61M	2.59M	3.53M	3.90M	3.63M
	Total Liabilities
9.10M	5.28M	9.65M	9.53M	9.62M
	Stockholders Equity
-3.93M	113.00K	-4.52M	-4.59M	-4.33M
Cash Flow		Free Cash Flow
-153.00K	846.00K	321.00K	-1.34M	-449.00K
	Operating Cash Flow
13.00K	929.00K	332.00K	-1.30M	-341.00K
	Investing Cash Flow
-171.00K	-83.00K	-11.00K	-45.00K	-108.00K
	Financing Cash Flow
-200.00K	0.00	250.00K	824.00K	654.00K

International Stem Cell Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISCO, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.11, and above the 200-day MA of 0.09, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.72 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ISCO.

International Stem Cell Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.04B	3.15	-44.58%	2.85%	16.08%	-0.27%
UPC	51 Neutral	$1.06M	―		―	―	―
ISCO	45 Neutral	$1.00M	―	-246.40%	―	16.64%	27.03%
BCLI	40 Underperform	$8.27M	―	234.90%	―	―	62.35%
WINT	28 Underperform	$3.18M	―	-120.01%	―	―	97.84%
SCPX	23 Underperform	$550.01K	―	-174.06%	―	-10.75%	82.25%